An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors
This is a prospective, open, single-center study evaluating the efficacy and safety of surufatinib Combined With Temozolomide and S-1 as the first-line treatment of advanced neuroendocrine tumors
Neuroendocrine Tumors
DRUG: Surufatinib Combined With Temozolomide and S-1
Objective response rate (ORR), the proportion of patients with complete response or partial response, using RESIST v1.1, approximately 1 years
Progression-Free Survival (PFS), time from first-dose to the first documented disease progression or death, approximately 1 years|Disease Control Rate (DCR), the proportion of patients with complete response, partial response or stable disease, using RESIST v1.1, approximately 1 years
This is a prospective, open, single-center study evaluating the efficacy and safety of surufatinib Combined With Temozolomide and S-1 as the first-line treatment of advanced neuroendocrine tumors